We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

FDA Approves First Transcatheter Device for Paravalvular Leak Closure

By HospiMedica International staff writers
Posted on 04 Nov 2026

Paravalvular leak is a backflow of blood around a surgical heart valve that can follow valve replacement, causing heart failure symptoms or hemolysis. More...

These leaks occur in 7%–17% of mitral valve replacements and 5%–10% of aortic valve replacements. A new device now offers a transcatheter option specifically designed to close these leaks without additional surgery.

The Amplatzer Paraclose PVL Occluder is a minimally invasive implant for paravalvular leak (PVL) closure around surgical replacement heart valves. It is designed to address the backflow that can occur when a small gap remains or develops between native tissue and the implanted valve. The system offers patients an alternative to repeat open‑heart surgery.

Implanted through a catheter inserted via an artery or vein in the leg, the device is positioned within the PVL to achieve closure. It features an oblong, elliptical shape with design elements intended to enable effective closure across diverse PVL anatomies. This transcatheter approach aims to reduce the need for another surgical procedure by sealing the leak percutaneously.

On October 28, 2026, Abbott received U.S. Food and Drug Administration (FDA) approval for the Amplatzer Paraclose PVL Occluder. The approval makes it the first and only transcatheter device in the United States specifically designed to treat PVL. The device is intended to close leaks that occur around surgical heart valves.

Regulatory authorization was supported by positive clinical data from the PARADIGM study, a prospective, multicenter, single‑arm investigation that includes 200 patients. Study findings reinforced the device’s safety and effectiveness for PVL closure. The study also demonstrated that the system provides an effective, minimally invasive alternative to open‑heart reoperation.

Outside the United States, the device is known as the Amplatzer Valvular Plug III and has been approved to treat PVL in Europe since 2020. Important safety information is available for U.S. use of the device. While Abbott’s broader Amplatzer portfolio includes occluders for congenital heart defects and stroke risk reduction, Paraclose is designed specifically for PVL.

“The U.S. approval of the Amplatzer Paraclose PVL Occluder addresses a significant treatment gap for people suffering from a paravalvular leak. Its unique elliptical shape is specifically designed to effectively close a wide range of PVL shapes and sizes that allows many patients to avoid another cardiac surgery,” said Amar Krishnaswarmy, M.D., section head of Invasive & Interventional Cardiology in the Robert and Suzanne Tomisch Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic.

“Offering this purpose-built device fills a critical unmet need as physicians treating PVL in the U.S. previously didn’t have an approved alternative to repeat open-heart surgery. The Amplatzer Paraclose PVL Occluder builds upon Abbott’s minimally invasive portfolio of structural heart devices that allows people with cardiovascular conditions to be effectively treated without the risk of surgical complications,” stated Sandra Lesenfants, senior vice president of Abbott's structural heart business.


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Gas Analyzer
GE SAM
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: A new automated approach could help predict which patients with dystonia will benefit from deep brain stimulation before surgery (Image Credit: Adobe Stock)

AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia

Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.